Abstract: A compound comprising a polyfluorinated anion of the formula [M1(XC(CFa(R1)b)(CFc(R2)d)R3)m(R4)n]−p and the use thereof is provided. Specifically, the present invention provides a compound comprising a anion which comprises a polyfluorinated alkoxide coordinated to a transition metal, or a Group III, IV or V element.

Abstract: A solvent composition for liquid delivery chemical vapor deposition of metal organic precursors, to form metal-containing films such as SrBi2Ta2O9 (SBT) films for memory devices. An SBT film may be formed using precursors such as Sr(thd)2(tetraglyme), Ta(OiPr)4(thd) and Bi(thd)3 which are dissolved in a solvent medium comprising one or more alkanes. Specific alkane solvent compositions may advantageously used for MOCVD of metal organic compound(s) such as &bgr;-diketonate compounds or complexes, compound(s) including alkoxide ligands, and compound(s) including alkyl and/or aryl groups at their outer (molecular) surface, or compound(s) including other ligand coordination species and specific metal constituents.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: A metalorganic complex of the formula:MA.sub.Y Xwherein:M is a y-valent metal;A is a monodentate or multidentate organic ligand coordinated to M which allows complexing of MAY with X;y is an integer having a value of 2, 3 or 4;each of the A ligands may be the same or different; andX is a monodentate or multidentate ligand coordinated to M and containing one or more atoms independently selected from the group consisting of atoms of the elements C, N, H, S, O and F.The metal M may be selected from the group consisting of Cu, Ba, Sr, La, Nd, Ce, Pr, Sm, Eu, Th, Gd, Th, Dy, Ho, Er, Tm, Yb, Lu, Bi, Tl, Y, Pb, Ni, Pd, Pt, Al, Ga, In, Ag, Au, Co, Rh, Ir, Fe, Ru, Sn, Li, Na, K, Rb, Cs, Ca, Mg, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, and W. A may be selected from the group consisting of .beta.-diketonates and their sulfur and nitrogen analogs, .beta.-ketoesters and their sulfur and nitrogen analogs, cyclopentadienyls, alkyls, perfluoroalkyls, alkoxides, perfluoroalkoxides, and Schiff bases.

Abstract: A method for depositing copper-based films and a copper source precursor for use in the chemical vapor deposition of copper-based films are provided. The precursor includes a mixture of at least one ligand-stabilized copper (I) .beta.-diketonate precursor; and at least one copper(II) .beta.-diketonate precursor. The method includes introducing into a deposition chamber: (i) a substrate; (ii) a copper source precursor in a vapor state including a mixture of at least one ligand-stabilized copper (I) .beta.-diketonate precursor; and at least one copper(II) .beta.-diketonate precursor; and (iii) at least one transport gas, different than said copper source precursor. The reaction substrate temperature is maintained at from about 50.degree. C. to about 500.degree. C. for a period of time sufficient to deposit a copper-based film on said substrate.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: A liquid precursor is provided for the formation of metal oxide films comprising a mixture of two ro more types of beta-diketonate ligands bound to one or more metals. For example, a liquid mixture was formed of the mixed aluminum beta-diketonates derived from two or more of the ligands 2,6-dimethyl-3,5-heptanedione; 2,7-dimethyl-3,5-heptanedione; 2,6-dimethyl-3,5-octanedione; 2,2,6-trimethyl-3,5-heptanedione; 2,8-dimethyl-4,6-nonanedione; 2,7-dimethyl-4,6-nonanedione; 2,2,7-trimethyl-3,5-octanedione; and 2,2,6-trimethyl-3,5-octanedione. Films of metal oxides are deposited from vaporized precursor mixtures of metal beta-diketonates and, optionally, oxygen or other sources of oxygen. This process may be used to deposit high-purity, transparent metal oxide films on a substrate. The liquid mixtures may also be used for spray coating, spin coating and sol-gel deposition of materials.

Abstract: A metalorganic complex of the formula:MA.sub.y Xwherein:M is a y-valent metal;A is a monodentate or multidentate organic ligand coordinated to M which allows complexing of MA.sub.y with X;y is an integer having a value of 2, 3 or 4; each of the A ligands may be the same or different; andX is a monodentate or multidentate ligand coordinated to M and containing one or more atoms independently selected from the group consisting of atoms of the elements C, N, H, S, O and F.The metal M may be selected from the group consisting of Cu, Ba, Sr, La, Nd, Ce, Pr, Sm, Eu, Th, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Bi, Tl, Y, Pb, Ni, Pd, Pt, Al, Ga, In, Ag, Au, Co, Rh, Ir, Fe, Ru, Sn, Li, Na, K, Rb, Cs, Ca, Mg, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, and W. A may be selected from the group consisting of .beta.-diketonates and their sulfur and nitrogen analogs, .beta.-ketoesters and their sulfur and nitrogen analogs, cyclopentadienyls, alkyls, perfluoroalkyls, alkoxides, perfluoroalkoxides, and Schiff bases.

Abstract: This invention provides compositions useful in MR imaging comprising a polymer comprising units comprising the residue of a chelating agent linked to a poly(alkylene oxide) moiety, the polymer having a paramagetic metal ion associated therewith.

Abstract: This invention provides compositions useful in MR imaging comprising a polymer comprising units comprising the residue of a chelating agent linked to a poly(alkylene oxide) moiety, the polymer having a paramagetic metal ion associated therewith.

Abstract: A novel titanium (III)-based .beta.-diketonate-coordinated compound is disclosed for catalyzing the polymerization reaction of syndiotactic polystyrenes. The titanium (III)-based compound is represented by the following formula 1: ##STR1## wherein X is a C.sub.1 .about.C.sub.12 alkoxy or amine group, or a halogen atom; R is a C.sub.1 .about.C.sub.12 alkyl, aryl, or alkylsilane group. Preferably, X is N(SiMe.sub.3).sub.2 -- or OMe--, and R is phenyl, methyl, or t-butyl. The titanium (III)-based compounds are prepared by reacting titanium trichloride with diketone and tetrahydrofuran to form an intermediate product, then reacting the intermediate product Ti(AcAc)Cl.sub.2 (THF).sub.2 with either aminosilane or alcohol.

Abstract: Glassy coatings are made by curing in situ a coating of a sol gel of tetraethoxysilicon, water, alcohol, and the alkoxides of: Al, Ti and Na; or of Na and Zr.The coating may be applied to teeth as a dental fissure sealant or varnish to protect restorations, or (if filled) as an inherently coloured cosmetic coating, or as a prophylactic coating.

Abstract: Compounds of the formula ##STR1## in which R is alkyl having up to 4 carbon atoms, n has an average value of at least 9, X is a radical of the formula --C(.dbd.O)--(NH--SO.sub.2).sub.m -- in which m is 0 or 1 and, if m is 1, the carbonyl group may be bonded to the oxygen atom or to the nitrogen atom, and each of the radicals A.sub.1, A.sub.2 and A.sub.3, independently of the others, is hydrogen or an acyl radical, and salts of salt-forming compounds of formula I, as well as metal complexes of compounds of formula I, in which A.sub.1, A.sub.2 and A.sub.3 are hydrogen can be used as metal chelators and as auxiliaries in diagnosis.

Abstract: A precursor used in an MOCVD reactor for production of thin films of certain metal oxides is stabilized by introducing a ligand into the precursor during the precursor synthesis and thereby protecting the precursor from premature oxidation, nucleation, and decomposition.

Abstract: In accordance with the present invention, there are provided coating solutions for forming transparent conductive ceramic coatings, said coating solutions being homogeneous solutions or dispersions of acetylacetonate chelate compound, conductive substances and, if necessary, silicon compound and/or alkoxides of metals other than silicon in mixtures of water and organic solvents, and substrates having thereon transparent conductive ceramic coatings formed from said coating solutions and uses thereof.

Abstract: A method and apparatus for the synthesis of .beta.-diketonates such as Pb(fod).sub.2 and Pb(thd).sub.2 for use as precursors in metalorganic chemical vapor deposition processes. Lead oxide and a medium of pentane and a protonated ligand (H-fod or H-thd) are combined in a flask and subjected to reaction-promoting ultrasonic waves. The flask is immersed in a water bath to maintain a constant cool temperature, and the flask may include one or more arms for cooling and circulation of the medium during the reaction.

Abstract: An aqueous composition suitable for use as a printing ink is provided which comprises an aqueous solution or emulsion of a film-forming polymer containing a titanium compound which is the reaction product of a titanium orthoester, a beta-diketone and a dihydric alcohol.Preferably the composition also contains a pigment or dye and other conventional printing ink additives.The titanium compounds enhance the adhesion and heat resistance properties of the compositions and in contrast to known additives do not lose their efficacy when the ink is stored for more than a few hours.

Abstract: Chemical vapor deposition precursors for depositing copper, silver, rhodium and iridium metals on substrates comprise ligand stabilized +1 metal beta-diketonate coordination complexes of said metals. Uses of such precursors in CVD processes are also provided.

Abstract: Macrocyclic derivatives of 1,4,7,10-tetraazacyclododecane of general formula (I) hereinbelow, wherein A is a group of formula (II) hereinbelow, in which R is H or alkyl or optionally substituted benzyl or a H(OCH.sub.2 CH.sub.2).sub.1-4-, Me(OCH.sub.2 CH.sub.2).sub.1-4-, or Et(OCH.sub.2 CH.sub.2).sub.1-4- group, X or O--R.sub.1, in which R.sub.1 is H or alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyhydroxyalkyl or a polyoxaalkyl group or X is --NR.sub.2 R.sub.3, in which R.sub.2 and R.sub.3 are H or alkyl, hydroxyalkyl, alkoxyalkyl or alkoxyhydroxyalkyl, and B.sub.1, B.sub.2 and B.sub.3 have the same meanings as A or are H or a group of formula (III) hereinbelow, in which R.sub.4 is H or alkyl, Y is a O--R.sub.5 group, wherein R.sub.5 is H or alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyhydroxyalkyl or a polyoxaalkyl group, or Y is a --NR.sub.6 R.sub.7 group, wherein R.sub.6 and R.sub.

Abstract: Compounds of formula I ##STR1## wherein R.sub.1 and R.sub.2, that can be the same or different, are hydrogen, alkyl, aryl, aralkyl groups or, if taken together, cycloalkyl groups;A is a carbon atom, a residue of 2,3-dioxybutandioic-2,4-dioxyphtalic acid or disubstituted malonic acid derivatives;n.sub.1 and n.sub.2 are selected in such a manner that the result of their addition is from 2 to 40;T.sub.1 and T.sub.2 that can be the same or different, are hydrogen, alkyl, benzyl, phenyl, acyl or cycloalkyl or a residue of formulae ##STR2## Compounds I are useful as anti-tumor agents in human therapy.

Abstract: A fluorine-containing platinum complex having anti-tumor activity of the formula: ##STR1## wherein R.sub.1 is a fluorine atom or a trifluoromethyl group,R.sub.2 is a fluorine atom, a hydrogen atom or a lower alkyl group,X is a halogen atom, a group of the formula: --NO.sub.2, or two Xs combined to form a group of the formulae: ##STR2## Y is a hydroxyl group or a halogen atom, and n is 0 or 1,and an anti-tumor composition comprising the same as an active ingredient.

Abstract: A process for making a solution of a complex of an oxamine and a polyvalent paramagnetic metal comprising contacting a solution of the oxamine with (a) the insoluble hydroxide of the polyvalent paramagnetic metal in water, or (b) an alkoxide of the metal is a non-aqueous solvent, thereby to form a solution of a complex of the oxamine and the metal. The complex, preferably ferrioxamine, is an improved NMR image enhancer compared even with ferrioxamine made conventionally, characterized by a high LD.sub.50.

Abstract: Methods and compositions for enhancing magnetic resonance imaging in at least a portion of a warm-blooded animal.

Abstract: The invention relates to a platinum-(II)-diamine complex having the formula et out below: ##STR1## to a method for the preparation of said compound, to a preparation with an antitumour action containing said compound, to shaped preparations with an antitumour action and to shaped preparations with an antitumour containing said compound.

Abstract: Platinum complexes of the general formula I[(R.sup.1 NH.sub.2).sub.n Pt].sub.q Y.sub.m X.sub.p (I)in which Y is a phosphonic acid ligand, and the preparation thereof, are described. The platinum complexes are suitable as active substances in pharmaceuticals, in particular for controlling cancers.

Abstract: A process for the vapor-phase synthesis of non-adduct volatile fluorinated and non-fluorinated metal-ligand complexes comprising contacting a .beta.-diketone or .beta.-ketoimine ligand with an inert carrier gas to vaporize the ligand, reacting the vaporized ligand with a metal species at a temperature sufficient to form the metal-ligand complex and recovering the metal-ligand complex by sublimation. The process is conducted in the absence of solvent thereby providing pure non-adduct metal-ligand complexes. Such complexes are particularly suited for specialty applications requiring use of high purity compounds.

Abstract: Platinum amine sulfoxide complexes of the formula [PtCl(diam)(R.sub.2 SO)].sup.+ X.sup.- wherein diam represents a bidentate amine, R is C.sub.3 -C.sub.7 alkyl or cycloalkyl and X.sup.- is an anion, exhibit favorable anti-tumor activity in vivo against tumors susceptible to therapy with platinum.

Abstract: A platinum complex having the following formula (I) is disclosed, ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different and each independently represents a methyl group or an ethyl group, and the configuration of 1,2-diaminocyclohexane is either cis-, trans-l-, trans-d-, or trans-dl-.The compound possess excellent antitumor activity with a high therapeutic index and abundant water solubility, and thus are effective as an antitumor agent.

Abstract: This disclosure sets forth a novel process for producing cisplatin analogs which possess antitumor activity.

Abstract: This disclosure sets forth a novel process for producing cisplatin analogs which possess antitumor activity.

Abstract: Titanium chelates with 1 to 2 acetoacetic acid ester ligands and one to two alkoxy groups per titanium atom the sum of these ligands and the alkoxy groups being three as well as Ti-O-Ti bridge between two titanium atoms are formed by release of alcohol and condensation of mono- or bis-acetoacetic acid ester-Ti-(IV)-chelates which have up to 4 alkoxy groups per titanium atom.

Abstract: A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom or a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.5 and R.sub.6 are each a hydrogen atom or a lower alkyl group) or a group represented by ##STR3## (wherein m is 1 or 2)].

Abstract: Organometallic compounds and compositions comprising a metal, an amido carboxyl moiety bonded to the metal, an active moiety bonded to the metal, and at least one modifier moiety sufficient to satisfy the valency of the metal. These compounds and compositions are capable of combining the substantivity of the amido carboxyl metal system, functional efficacy of an active moiety, and film-forming properties in a single compound or composition.

Abstract: The invention relates to novel 2-acyl-1,3-cyclohexanediones and the oxime ethers thereof with herbicidal and plant growth regulating properties.The novel 2-acyl-1,3-cyclohexanediones and the oxime ethers thereof are of the formula I ##STR1## wherein A is a 2- or 7-membered alkylene bridge, or a 3- to 7-membered alkenylene bridge which may be mono- or polyunsaturated,n is 0, 1 or 2,R.sub.1 is C.sub.1 -C.sub.4 alkyl or benzyl,R.sub.2 is C.sub.1 -C.sub.6 alkyl which is unsubstituted or substituted by halogen, C.sub.1 -C.sub.4 alkoxy or C.sub.1 -C.sub.4 alkylthio; or is C.sub.3 -C.sub.6 cycloalkyl; or phenyl, benzyl or phenylethyl, the phenyl ring of each of which may be substituted by ahlogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 haloalkoxy, cyano or nitro,X is oxygen or a radical --NOR.sub.3, andR.sub.3 is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 haloalkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 haloalkenyl or C.sub.3 -C.

Abstract: Novel organic platinum complex of the formula: ##STR1## wherein R.sup.1 is hydrogen atom or a lower alkyl group; R.sup.2 is hydrogen atom, a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a lower alkynyl agroup, a lower alkoxy group, a lower alkanoyl group, amino group, a substituted or unsubstituted nitrogen-containing hetero-monocyclic group, or an oxygen-containing hetero-monocyclic group, Alk is a lower alkylene group, X is carbonyl or sulfonyl group, n is 1 or 2, which has excellent anti-tumor activity against various tumors and is useful as an anti-tumor agent, and a process for the preparation thereof, and a pharmaceutical composition containing said compound.

Abstract: Novel organic platinum complex of the formula: ##STR1## wherein R.sup.1 is hydrogen atom or a lower alkyl group, R.sup.2 is a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a lower alkanoyl group, a mono- or di-lower alkylamino group, a substituted or unsubstituted nitrogen-containing hetero-monocyclic group, an oxygen-containing hetero-monocyclic group, or a group of the formula:--CH.sub.2 O(CH.sub.2 CH.sub.2 O).sub.m CH.sub.3, X is carbonyl group or sulfonyl group, m is an integer of 1 or 2,which has excellent anti-tumor activity against various tumors and is useful as an anti-tumor agent, and a process for the preparation thereof, and a pharmaceutical composition containing said compound.

Abstract: A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom or a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.5 and R.sub.6 are each a hydrogen atom or a lower alkyl group) or a group represented by ##STR3## (wherein m is 1 or 2)].

Abstract: A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1 and R.sub.2 are each a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.3 and R.sub.4 are each a hydrogen atom or a lower alkyl group) or a group represented by ##STR3## (wherein m is 1 or 2)].

Abstract: Certain cobalt(II) complexes such as secondary amine adducts of cobalt(II) acetylacetonate have been found useful as latent catalysts for anhydride-epoxy blends.

Abstract: New platinum (IV) complexes are now provided, which exhibit antitumor activity as shown by the tests on mouse leukemia, L-1210 cell in mice. These new platinum (IV) complexes contain 1,2-cyclohexanediamine or 2-(aminomethyl)cyclohexyl-amine as a ligand.

Abstract: Novel compounds for absorbing carbon monoxide and olefinically-unsaturated compounds from feedstreams are of the formula ##STR1## wherein R.sub.1 is trichloromethyl or R.sub.F ; R.sub.F is C.sub.n F.sub.2n+1 and n is 1-8; R.sub.2 is H or hydrocarbyl of 2-20 carbon atoms having at least one olefinic unsaturated bond; M.sup.I is Cu.sup.I or Ag.sup.I and R.sub.3 is hydrocarbyl of 2-20 carbon atoms having at least one olefinic unsaturated bond.

Abstract: A zirconia-based coating composition comprising a mixture obtained by mixing:(a) at least one compound selected from the group consisting of (a') a zirconium compound represented by the general formula (I):Zr(OR).sub.4 (I)wherein R is an alkyl group having 2-5 carbon atoms or the general formula (I'):Zr(OR).sub.4.ROH (I')wherein R has the same means as defined above, (a") a partial hydrolyzate of the zirconium compound (a'), and (a'") a partial condensate of the partial hydrolyzate (a"),(b) a .beta.-diketone or .beta.-ketoester represented by the general formula (II):R.sup.1 COOH.sub.2 COR.sup.2 (II)wherein R.sup.1 is an alkyl group having 1-5 carbon atoms, R.sup.2 is an alkyl group having 1-5 carbon atoms or an alkoxy group having 1-4 carbon atoms),(c) water, and(d) a hydrophilic organic solvent.

Abstract: Novel platinum(II) carboxylatocomplexes of the following general formula: ##STR1## wherein R is tetrahydrofurfuryl or cyclo-C.sub.n R".sub.2n-1, R" is H, an alkyl, hydroxyl, n=3-6; R' is --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --CH(OH)--, --CH(OH)--CH.sub.2 --, --CH(OH)--CH(OH)--.These compounds possess a clearly pronounced antitumor activity and are readily soluble in water.A process for preparing these compounds comprises reacting K [PtCl.sub.3 NH.sub.3 ] with KI, followed by treatment of the reaction mixture with tetrahydrofurfurylamine or an alicyclic amine and treatment of the resulting mixture of complexes with a silver salt of the formula: Ag.sub.2 (OOC--R'--COO), wherein R' is as identified above.

Abstract: A treated decomposable compound of molybdenum, which has been prepared by the catalytic dehydrogenation of a decomposable compound of molybdenum wherein the molybdenum has a valence state greater than zero or by the treating of the decomposable compound of molybdenum with a reducing agent, is mixed with a hydrocarbon-containing feed stream. The hydrocarbon-containing feed stream containing such treated decomposable compound of molybdenum is then contacted with a catalyst composition comprising a support selected from the group consisting of alumina, silica and silica alumina and a promoter comprising at least one metal selected from the group consisting of Group VIB, Group VIIB, and Group VIII of the Periodic Table to reduce the concentration of metals, sulfur, nitrogen, Ramsbottom carbon residue and/or heavies contained in the hydrocarbon-containing feed stream.

Abstract: There are disclosed compounds having the formula ##STR1## wherein R and R' are selected from the group consisting of (a) substituents having the formula R.sup.1 R.sup.2 R.sup.3 C-wherein R.sup.1 is H or an alkyl group of 1 to 6 carbon atoms, and R.sup.2 and R.sup.3 are independently alkyl of 1 to 6 carbon atoms;(b) phenyl group;(c) phenyl group substituted by Br, Cl, F, alkyl group of 1 to 10 carbon atoms, or alkoxy group of 1 to 10 carbon atoms; and(d) an adamantyl group; and M is As or Sb; with the proviso that when R and R' are phenyl or substituted phenyl in which the substituents are in meta or para positions, M is As. Preferably R and R' are the same and are t-butyl, phenyl or adamantyl. The compounds display thermochromic properties.

Abstract: Homologs of Diamide-DTPA-Paramagnetic compounds (such as diamido acetyl diethylene triamine triacetic acid) provide excellent contrast agents for magnetic resonance (MR) imaging. The magnetic dipole generated by the unpaired electron within the paramagnetic (PM) atom, causes a local reduction in the bulk magnetic field of the MR system. The resulting shorting of the T1 (spin lattice) relaxation time in the local hydrogen protons within the area of interest, causes an intense "free induction signal" and a corresponding modulation in the collected scanning data. The tissue or organ of interest appears on the MR display highlighted in white. Background tissue is displayed as darker or lower intensity greys. A surface highlighted image of the small and large intestine may be obtained by venous injection of the diamide contrast agent. The contrast agent is formed by replacing two carboxylic acids on the DTPA chelator with functional amide groups.

Abstract: Homologs of Diester-DTPA-Paramagnetic compounds (such as dimethyl acetyl diethylene triamine triacetic acid) provide excellent contrast agents for magnetic resonance imaging (MRI). The magnetic dipole generated by the unpaired electron within the paramagnetic (PM) atom, causes a local reduction in the bulk magnetic field of the MRI system. The resulting shorting of the T1 (spin lattice) relaxation time in the local hydrogen protons within the area of interest, causes an intense "free induction signal" and a corresponding modulation in the collected scanning data. The tissue or organ of interest appears on the MRI display highlighted in white. Background tissue is displayed as darker or lower intensity greys. The ester homologs replace two carboxylic acids to form functional ester groups on the DTPA chelator. The homologs cause the Diester-DTPA-PM contrast agents to go into solution readily, and promotes organ selectivity.

Abstract: The present invention relates to new titanium acetylacetonates. The new compounds contain one or two glycol ether groups bound to the central titanium atom. Their solutions in glycol ethers yield, after dilution with water down to chelate contents as low as 1 percent by weight, stable solutions which, even after several months of standing, display neither precipitation nor turbidity.

Abstract: The present invention relates to new titanium chelates containing both acetylacetone and malonic acid dialkyl ester as chelating agents. The acetylacetone moiety is contained in these new chelates in amounts between 1.25 and 1.95 moles and the malonic acid dialkyl ester moiety in amounts between 0.05 and 0.75 moles per gram-atom of titanium. The new chelates have the same properties as the known titanium acetylacetonates; however, they have the advantage that they are only slightly yellow and in many applications they have an improved stability.

Abstract: Organic titanium chelates which contain only acetylacetone and triethanolamine as ligands and chelating agents and are soluble in glycol ethers are disclosed. The addition of even a small amount of the glycol ether to these new substances improve the stability of their aqueous solutions in an extraordinary manner. Preferably, solutions of 50 to 80% of these new chelates are used, from which very dilute aqueous solutions, i.e., 1 to 5% of extraordinarily high stability can be made.